← Eichor
Study identifier: NCT04036357 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Liver Damage and Cardiometabolic Disorders in NAFLD

Condition: NAFLD · Liver Fibroses · Cardiovascular Diseases  ·  Sponsor: University of Roma La Sapienza

PhaseN/A
Planned participants2000
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.

This description comes directly from the study's public registry record.

Talk to the study team

Francesco Baratta, MD, PI.  ·  +390649972249  ·  francesco.baratta@uniroma1.it

Daniele Pastori, MD, PI.  ·  +390649972249  ·  daniele.pastori@uniroma1.it

Always discuss trial participation with your own doctor first.

Locations (1)

Day Service of Internal Medicine and Metabolic Disorders - Policlinico Umberto I - Sapienza University of RomeRome, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04036357